首页> 美国政府科技报告 >Biological and Clinical Characterization of Novel lncRNAs Associated with Metastatic Prostate Cancer.
【24h】

Biological and Clinical Characterization of Novel lncRNAs Associated with Metastatic Prostate Cancer.

机译:与转移性前列腺癌相关的新型lncRNa的生物学和临床表征。

获取原文

摘要

LncRNA are polyadenylated RNA species that are more than 200bp in length and are implicated in development of variety of cancers including prostate cancer. In this study we have identified PCAT29 as the first androgen receptor repressed lncRNA that functions as a tumor suppressor. We show that loss of PCAT29 may identify a subset of patients at higher risk for disease recurrence. Collectively, PCAT29 is a tumor-suppressive lncRNA of prognostic and therapeutic relevance in prostate cancer. In addition, we have performed transcriptome analysis to identify a set of AR regulated lncRNAs. AR plays a critical role in the development and progression of prostate cancer. AR regulates a large repertoire of genes; however, its role in Long non-coding RNAs (lncRNA) regulation remains unclear. With this compendium of AR regulated lncRNA, we will be able to identify lncRNAs that play important role in prostate cancer development and progression.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号